Why the study?
Does CY 216 (low molecular weight heparin) improve antithrombotic efficacy compared to standard heparin in a rat model of venous thrombosis?
Does CY 216 (low molecular weight heparin) improve antithrombotic efficacy compared to standard heparin in a rat model of venous thrombosis?
In a rat model of venous thrombosis, low molecular weight heparin (CY 216) demonstrated effective antithrombotic properties at low doses where standard heparin was ineffective.
Supports low-dose LMWH exploration in preclinical thrombosis; hypothesis-generating and should not yet change clinical practice.
In a venous thrombosis model in the rat obtained by ligation of the inferior vena cava, the effects of standard heparin and CY 216, a low molecular weight heparin fraction, are compared. At a dosage of less than 2 mg/kg b.w. CY 216 is an effective antithrombotic, whereas standard heparin is not.
No takes yet. Share an insight, caveat, or question.
Doutremepuich et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: